Skip to main content
. 2013 Apr;33(7):1303–1316. doi: 10.1128/MCB.00858-12

Fig 5.

Fig 5

SCFA are agonists of PPARγ. (A) Stable GAL4-PPAR chimera reporter assay showing activation of PPARγ but not PPARα and PPARδ by SCFA at concentrations of ≥1 mM. The dotted lines represent the levels of luciferase activity reached upon incubation with synthetic PPAR agonists. Cells were treated for 24 h. Error bars represent SD. (B) Stable PPARγ reporter assay showing activation of PPARγ by SCFA at concentrations of ≥500 μM. Cells were treated for 24 h. Note the different x axis for rosiglitazone and the SCFA. Error bars represent SD. (C) A nuclear receptor PamChip assay was used to measure the interaction between PPARγ and immobilized peptides corresponding to specific coregulator-nuclear receptor binding regions in the presence and absence of rosiglitazone (1 μM), butyrate (40 mM), or acetate (40 mM). Representative images are shown. (D) Quantitation of the PamChip assay results for rosiglitazone and butyrate compared to the control. Arrows point to the same peptides as those described for panel C.